Evidence map›Paper›PMID 42467141›Full record

ArticleAnnals of biomedical engineering2026

Microfluidic Precision Engineered Artificial GARP Presenting Cells for Regulatory T-Cell Induction.

Hsiu-Ping Yi, Sudhanshu Agrawal, Giovanni Hau Lai Tam, Nicole Fong, Jui-Yi Chen, Anshu Agrawal, Abraham P Lee

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of biomedical engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hsiu-Ping YiBiomedical Engineering, University of California Irvine, Irvine, CA, USA.
Sudhanshu AgrawalDivision of Basic and Clinical Immunology, Department of Medicine, University of California Irvine, Irvine, CA, USA.
Giovanni Hau Lai TamBiomedical Engineering, University of California Irvine, Irvine, CA, USA.
Nicole FongBiomedical Engineering, University of California Irvine, Irvine, CA, USA.
Jui-Yi ChenBiomedical Engineering, University of California Irvine, Irvine, CA, USA.
Anshu AgrawalDivision of Basic and Clinical Immunology, Department of Medicine, University of California Irvine, Irvine, CA, USA. aagrawal@uci.edu.
Abraham P LeeBiomedical Engineering, University of California Irvine, Irvine, CA, USA. aplee@uci.edu.ORCID http://orcid.org/0000-0001-8378-6616

Funding

Microfluidic Precision Engineered Artificial Antigen Presenting Cells for Cancer ImmunotherapyR33CA267258 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI AGRAWAL, ANSHU, LEE, ABRAHAM P · 2022 to 2025
$1.1M
NCI NIH HHS R33 CA267258NIH HHS R33CA267258
6 · The paper itself

Abstract

purposeThe incidence of autoimmune diseases has increased in Western societies, highlighting the need for novel treatment strategies. Current therapies, including biologics, are limited by high costs, potential adverse effects, and often lack specificity and long-term efficacy. Regulatory T cells (Tregs) are crucial for maintaining immune tolerance and represent a promising target for autoimmune disease therapies. However, current methods for inducing Tregs, such as in vitro cytokine combinations and in vivo antigen-specific approaches, face challenges in stability and effectiveness. This research aims to develop an innovative artificial cell platform to enhance Treg induction for autoimmune disease treatment.

methodsThis study developed artificial GARP-presenting cells (aGPCs), an innovative artificial cell platform designed to mimic natural cellular functions and enhance Treg induction. We evaluated aGPC efficacy in inducing Tregs both in vitro and in vivo, comparing results with control groups. Treg populations, suppression assay, cytokine profiles (IL-10 and IFN-γ), and biocompatibility were assessed.

resultsThe current study demonstrates that aGPCs significantly increase the induction of Tregs both in vitro and in vivo compared to control groups. The aGPC-GARP

conclusionThese findings suggest that aGPCs could be applied to Treg-based therapies and hold promise for developing antigen-specific treatments for inflammatory disorders and autoimmune diseases.

Indexed as

Artificial cellsCellular immunotherapiesGlycoprotein A repetitions predominant (GARP)MicrofluidicsRegulatory T cells

Identifiers

PMID42467141

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.